Physician profile
Jaskaran S Bedi
NPI 1306831896
$7,152.33
in general payments reported to CMS, 2019-2025
42 companies · $1,240 in 2025
The $1,240 reported for 2025 was more than what 88% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $808 · 2020: $422 · 2021: $1,314 · 2022: $1,430 · 2023: $1,094 · 2024: $844 · 2025: $1,240.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,179.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,178.95 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $1,230.22 | 2019-2024 | Xarelto |
| Glaxosmithkline, LLC. | $1,156.16 | 2019-2025 | Trelegy Ellipta, Arexvy |
| Ironwood Pharmaceuticals, INC | $426.53 | 2019-2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $414.42 | 2021-2024 | |
| Amgen INC. | $358.56 | 2019-2025 | Repatha, Otezla |
| Phathom Pharmaceuticals, INC. | $312.43 | 2024-2025 | Voquezna |
| Actelion Pharmaceuticals US, INC. | $274.12 | 2025 | Opsumit, Uptravi |
| Lilly USA, LLC | $260.16 | 2019-2024 | Jardiance, Mounjaro, Emgality |
| Pfizer INC. | $259.48 | 2020-2023 | |
| Astrazeneca Pharmaceuticals LP | $225.40 | 2019-2025 | Farxiga, Lokelma |
| Otsuka America Pharmaceutical, INC. | $192.36 | 2023 | Rexulti |
| Novo Nordisk INC | $177.13 | 2019-2025 | Ozempic, Rybelsus |
| Eisai INC. | $168.65 | 2021-2025 | |
| Novartis Pharmaceuticals Corporation | $146.48 | 2019-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $144.94 | 2020-2024 | Jardiance |
Show all 42 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jaskaran Bedi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.